Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a conference call tomorrow, November 6, 2025, at 14:00 C ...